Table 1.
Demographic data of the study cases.
| Variable | All cases (n = 500) |
|---|---|
| Age, years | 51 (10-64) |
| Gender | |
| Male | 446 (89.2%) |
| Female | 54 (10.8%) |
| Body mass index (kg/m2) | 28.6 (16.7-42.5) |
| Child-Pugh score | 9 (5-15) |
| MELD score | 15 (6-48) |
| Virology | |
| HCV | 453 (90.6%) |
| HBV | 8 (1.6%) |
| Blood group | |
| A –ve | 12 (2.4%) |
| A +ve | 166 (33.2%) |
| AB –ve | 3 (0.6%) |
| AB +ve | 36 (7.2%) |
| B –ve | 6 (1.2%) |
| B +ve | 116 (23.2%) |
| O –ve | 16 (3.2%) |
| O +ve | 131 (26.2%) |
| Waiting period | 5.5 (1-50) |
| Indication | |
| HCV | 323 (64.6%) |
| HBV | 6 (1.2%) |
| HCV + HBV | 2 (0.4%) |
| HCC | 146 (29.2%) |
| BCS | 6 (1.2%) |
| Autoimmune | 11 (2.2%) |
| Cryptogenic | 5 (1%) |
| Sclerosing cholangitis | 1 (0.2%) |
MELD, model for end stage liver disease; HCV, hepatitis C virus; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; BCS, Budd Chiari syndrome.